MedicineEngineering

Comment on TWO Versus Five-fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial.

R. Romrattaphan, P. Dankulchai, T. Prasartseree, W. Sittiwong, W. Thaweerat, S. Junlabut, S. Nitipitch

2026.2.1CLINICAL ONCOLOGY

DOI: 10.1016/j.clon.2026.104100

Abstract

Abstract is not available.

Citation format

ROMRATTAPHAN, R., et al. Comment on TWO versus five-fraction magnetic resonance-guided adaptive radiotherapy with dominant-targeted boost in localized prostate cancer (DOTA-2): Interim acute toxicity analysis of the phase II randomised trial. CLINICAL ONCOLOGY, 2026, 53: 104100.